{
  "ptid_time": "129_S_4073_2011-06-20",
  "img_path": "/data/qiuhui/data/adni/images/129_S_4073/2011-06-20/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 37,949 mm³, 1.5% below the reference mean. With a Z-score of -0.04 (48.6th percentile), this represents normal volume ; hippocampal volume measures 7,352 mm³, 2.7% below the reference mean. With a Z-score of -0.27 (39.5th percentile), this represents normal volume ; whole brain volume measures 993,737 mm³, 7.9% below the reference mean. With a Z-score of -1.03 (15.1th percentile), this represents mild atrophy; entorhinal cortex volume measures 2,962 mm³, 27.8% below the reference mean. With a Z-score of -1.88 (3.0th percentile), this represents moderate atrophy; fusiform gyrus volume measures 14,996 mm³, 20.4% below the reference mean. With a Z-score of -1.74 (4.1th percentile), this represents moderate atrophy; middle temporal gyrus volume measures 20,437 mm³, 4.2% below the reference mean. With a Z-score of -0.38 (35.2th percentile), this represents normal volume . ",
  "text_data": "Age is 76.2 years. Gender is Male. Education: 11 years. Handedness: Left. Race: White. Medical history: Neurologic; Head, Eyes, Ears, Nose and Throat; Cardiovascular; Respiratory; Dermatologic-Connective Tissue; Musculoskeletal; Renal-Genitourinary; Alcohol Abuse; Smoking; Major Surgical Procedures. MMSE: 28.0. MoCA: 23.0. Logical Memory: 7.0. Laboratory findings: Monocytes: 0.73 (profound elevated); WBC: 9.61 (significant elevated); Creatine Kinase: 271.00 (profound elevated); Triglycerides (GPO): 236.00 (significant elevated). APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.36 SUVR (significant elevated); Amyloid beta: 836.70 pg/mL (normal ); Total tau: 164.80 pg/mL (normal ); Phosphorylated tau: 15.34 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging shows mild whole brain atrophy and moderate atrophy in the entorhinal cortex and fusiform gyrus—key regions affected in Alzheimer’s. However, CSF biomarkers (Aβ, T-tau, P-tau) are normal, and amyloid PET (AV45) is elevated, suggesting possible early amyloid deposition without downstream neurodegeneration. Cognitive scores (MMSE 28, MoCA 23) indicate subtle deficits but not dementia.  \n**Diagnosis:** **Mild Cognitive Impairment (MCI)**  \n**Confidence:** **Medium** (Conflicting biomarker patterns: AV45 elevation suggests amyloid pathology, but normal CSF and preserved hippocampi complicate a clear Alzheimer’s diagnosis.)  \n\n**Key Points:**  \n- **Structural changes:** Entorhinal/fusiform atrophy aligns with early AD, but hippocampal sparing is atypical.  \n- **Biomarkers:** Elevated AV45 hints at amyloidosis, yet normal CSF argues against active neurodegeneration.  \n- **Cognition:** MoCA 23 suggests MCI, but MMSE 28 is near-normal, warranting longitudinal follow-up.  \n\n**Note:** APOE4-negative status reduces AD risk, but AV45+ suggests alternative amyloid pathways. Consider non-AD etiologies (e.g., LATE-NC) given hippocampal sparing.",
  "timestamp": "2025-07-26T14:13:40.587410"
}